STOCK TITAN

P3 Health Partners Warrant (PIIIW) Stock Price, News & Analysis

PIIIW NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
123 216 sessions, November 3, 2025 to November 3, 2026
Largest daily move
+1465.2% close of May 15, 2026
1-year change
-23% closing prices, November 3, 2025 to November 3, 2026
1-month change
-35.8% closing prices, October 2, 2026 to November 3, 2026

Company Description

P3 Health Partners Inc. (warrants trading under the symbol PIIIW on The Nasdaq Stock Market LLC) is described as a patient-centered and physician-led population health management company. According to company disclosures, P3 focuses on value-based care, with physicians, clinicians and support professionals working together to manage patient health and healthcare utilization.

The company states that its model aggregates and supports existing healthcare resources in local communities to build a network of providers. These providers work in a coordinated and integrated way with the stated goals of improving patient outcomes, lowering healthcare costs and enhancing the experience for patients, providers and caregivers. P3 emphasizes physician leadership, the use of data and technology, and community outreach tools as core elements of its approach to population health management.

P3 notes that it receives fixed per-member-per-month fees under capitation arrangements for certain Medicare Advantage members it describes as "at-risk members." These members are a key performance metric monitored by the company, and P3 uses measures such as Adjusted EBITDA and Adjusted EBITDA per member per month (PMPM) to evaluate operating trends in connection with those populations. The company has discussed its business in terms of at-risk Medicare Advantage membership growth and related revenue trends.

Public filings and news releases indicate that P3 Health Partners Inc. is the parent of P3 Health Group, LLC, which is identified as a borrower under a term loan agreement. Amendments to this term loan agreement have addressed matters such as interest-only periods, maturity dates, interest rate structure, paid-in-kind interest options and lender board observation rights. These financing arrangements form part of the company’s capital structure and are disclosed in its current reports on Form 8-K.

P3 has also highlighted that it uses non-GAAP financial measures, including Adjusted EBITDA and Adjusted EBITDA PMPM, in addition to GAAP results. The company explains that these non-GAAP measures adjust for items such as mark-to-market warrant expense, premium deficiency reserves, stock-based compensation, transaction expenses and related litigation fees. Management states that these measures are used to evaluate ongoing operating results and trends, particularly in the context of its value-based care and population health management activities.

In its communications, P3 describes itself as founded and led by physicians and organized as a team of doctors, clinicians and support service professionals with a shared focus on value-based care. The company has discussed national expansion and participation in healthcare investor conferences, reflecting engagement with the capital markets following its business combination and listing on Nasdaq under the common stock symbol PIII and warrant symbol PIIIW.

Business focus and operating model

According to P3, its business is centered on managing the health of defined patient populations, particularly Medicare Advantage members under capitation arrangements. The company indicates that it leverages a deeply integrated and capital efficient care model, supported by data, technology and physician leadership. By coordinating care among community providers, P3 aims to influence clinical outcomes and the cost of care for the populations it serves.

The company’s disclosures emphasize that COVID-19 has affected its operations, particularly because many of its patients are older adults with chronic illnesses. P3 has noted that it expects COVID-19-related costs to be a factor in its financial results, while also indicating that it views the impact as transitory over the longer term. These comments are framed in the context of its value-based care model and the health needs of its patient base.

Capital structure and warrants

SEC filings identify Warrants exercisable for one share of Class A common stock trading under the symbol PIIIW on Nasdaq. These filings also describe P3 Health Partners Inc. as the registrant and parent company of P3 Health Group, LLC. The company has entered into amendments to its term loan agreement that modify payment structures, interest rates, paid-in-kind interest options and lender rights, illustrating how it manages its debt obligations over time.

Current reports on Form 8-K also disclose corporate governance developments, such as the resignation of a director and the appointment of a new director who also serves as Chief Executive Officer. These filings provide insight into board composition and the relationship between management and the board.

Use of non-GAAP metrics and key performance indicators

P3 explains that it monitors at-risk Medicare Advantage membership as a key performance metric, representing the approximate number of members for whom it receives fixed per-member-per-month fees under capitation arrangements. The company also reports Adjusted EBITDA and Adjusted EBITDA PMPM as non-GAAP measures. It provides reconciliations to GAAP measures in its financial disclosures and notes that these metrics are used to evaluate operating performance and trends in its population health management business.

The company cautions that these non-GAAP measures have limitations, as they reflect management’s judgments about which items to exclude or include, and that other companies may calculate similar measures differently. P3 presents these metrics alongside GAAP results in its financial communications.

Stock information

According to SEC filings, the PIIIW warrants are listed on The Nasdaq Stock Market LLC. These warrants are exercisable for one share of P3 Health Partners Inc. Class A common stock. Investors reviewing PIIIW may consider both the warrant terms disclosed in SEC filings and the underlying business of P3 Health Partners Inc. as described in its public statements and reports.

Stock Performance

$0.0083
+7.79%
+0.0006
After hoursLast updated: November 4, 2026 at 16:45
-23%
Performance 1 year

P3 Health Partners Warrant (PIIIW) closed at $0.0077 on November 3, 2026. Over the past 12 months, the price has lost 23.0%.

See what a $1,000 investment in PIIIW would be worth today

Average down calculator for PIIIW

PIIIW Metrics & Rankings

Month to date
-28.7%
View ranking
YTD
-23.0%
View ranking

Price returns through November 3, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

P3 Health Partners Warrant has 2 recent news articles. Of the recent coverage, 2 articles coincided with positive price movement and 0 with negative movement. Key topics include earnings, conferences. View all PIIIW news →

Financial Highlights

P3 Health Partners Warrant generated $1.5B in revenue in FY2025, operating income reached -$270.3M (-18.5% operating margin), and net income was -$147.9M, reflecting a -10.1% net profit margin. Diluted earnings per share stood at -$45.26. The company generated -$91.2M in operating cash flow. The current ratio was 0.24, measuring current assets divided by current liabilities.

$1.5B
Revenue (FY2025)
-$147.9M
Net Income (FY2025)
-$91.2M
Operating Cash Flow

Upcoming Events

No upcoming events scheduled for PIIIW.

Short Interest History

Last 12 Months

Short interest in P3 Health Partners Warrant (PIIIW) currently stands at 386.8 thousand shares, down 2.8% from the previous reporting period. Since November 2025, short interest has increased by 10729.1%.

Days to Cover History

Last 12 Months

Days to cover for P3 Health Partners Warrant (PIIIW) currently stands at 1.1 days, up 13% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 1.0 to 63.0 days.

PIIIW Company Profile & Sector Positioning

P3 Health Partners Warrant (PIIIW) and is listed on the NASDAQ.

Investors comparing PIIIW often look at related companies in the same sector, including Surgery Partners, Inc. (SGRY), Guardian Pharmacy Services, Inc. (GRDN), Astrana Health Inc. (ASTH), AMN Healthcare Services (AMN), and Ardent Health, Inc. (ARDT). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate PIIIW's relative position within its industry.

Frequently Asked Questions

The current stock price of P3 Health Partners Warrant (PIIIW) is $0.0083 in after-hours trading as of November 4, 2026.

The FY2025 revenue of P3 Health Partners Warrant (PIIIW) is $1.5B, from its most recent completed fiscal year.

The FY2025 net income of P3 Health Partners Warrant (PIIIW) is -$147.9M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of P3 Health Partners Warrant (PIIIW) is -$45.26 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of P3 Health Partners Warrant (PIIIW) is -$91.2M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of P3 Health Partners Warrant (PIIIW) is -10.1% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of P3 Health Partners Warrant (PIIIW) is -18.5% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The current ratio of P3 Health Partners Warrant (PIIIW), current assets divided by current liabilities, was 0.24 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of P3 Health Partners Warrant (PIIIW) is -$270.3M for FY2025, its most recent completed fiscal year. Learn about operating income.

P3 Health Partners Inc. describes itself as a patient-centered and physician-led population health management company. It focuses on value-based care by aggregating and supporting community healthcare resources to coordinate and integrate care for defined patient populations.

The company states that it leverages a deeply integrated and capital efficient care model, supported by data, technology, physician leadership and community outreach tools. This model is intended to improve patient outcomes and experiences, increase provider and caregiver satisfaction, and lower care costs.

P3 defines at-risk members as Medicare Advantage members for whom it receives a fixed per-member-per-month fee under capitation arrangements. The number of these at-risk Medicare Advantage members is a key performance metric the company monitors to evaluate its business.

According to SEC filings, warrants exercisable for one share of P3 Health Partners Inc. Class A common stock trade under the symbol PIIIW on The Nasdaq Stock Market LLC.

P3 reports non-GAAP measures including Adjusted EBITDA and Adjusted EBITDA per member per month (PMPM). These adjust GAAP net income or loss for items such as interest, taxes, depreciation, amortization, mark-to-market warrant expense, premium deficiency reserves, stock-based compensation, transaction expenses and related litigation fees.

The company has stated that COVID-19 affects its results because many of its patients are older adults with chronic illnesses. It expects to incur COVID-19-related costs and has described the impact as transitory, noting that the ultimate effect depends on factors such as new variants and case volumes in its markets.

SEC filings identify P3 Health Group, LLC as a subsidiary of P3 Health Partners Inc. P3 Health Group, LLC is the borrower under a term loan agreement that has been amended to modify payment structures, interest rates, paid-in-kind interest options and lender rights.

Recent Forms 8-K have disclosed items such as amendments to the company’s term loan agreement and changes in the composition of its Board of Directors, including a director’s resignation and the appointment of a new director who also serves as Chief Executive Officer.

P3 explains that non-GAAP measures like Adjusted EBITDA and Adjusted EBITDA PMPM provide an additional tool for evaluating ongoing operating results and trends and for comparing its performance with other companies. It also notes that these measures have inherent limitations and should not be considered in isolation from GAAP results.

The company describes its team of doctors, clinicians and support service professionals as sharing a passion for delivering value-based care. Their focus is on coordinating and integrating care to improve outcomes and experiences while managing costs for the populations P3 serves.